For our group of poor responders treated during AHI, CD4/CD8 ratio at baseline was higher than in participants treated during chronic HIV infection, reflecting less immune dysregulation at the earliest stages of infection [23, 27, 30]. The gene discussed is CD4; the disease is HIV infectious disease.